Innovative solutions to novel drug development in mental health - Test2 - elhamkhani - TriplyDB

Innovative solutions to novel drug development in mental health

Innovative solutions to novel drug development in mental health

http://www.wikidata.org/entity/Q28677399

about

Effect of Pharmacological Interventions on the Fronto-Cingulo-Parietal Cognitive Control Network in Psychiatric Disorders: A Transdiagnostic Systematic Review of fMRI Studies Cognitive biases in binge eating disorder: the hijacking of decision making The Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people Improving and accelerating drug development for nervous system disorders Targeting Functional Biomarkers in Schizophrenia with Neuroimaging.Neuroimaging and neuromodulation approaches to study eating behavior and prevent and treat eating disorders and obesity Role of the axonal initial segment in psychiatric disorders: function, dysfunction, and intervention Diagnostic and therapeutic utility of neuroimaging in depression: an overview The expanding scope of psychiatric epidemiology in the 21st century A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation.Oxytocin affects the connectivity of the precuneus and the amygdala: a randomized, double-blinded, placebo-controlled neuroimaging trial.The promise of biological markers for treatment response in first-episode psychosis: a systematic review.Identifying a kinase network regulating FGF14:Nav1.6 complex assembly using split-luciferase complementation.Involvement of the catecholaminergic system on the antidepressant-like effects of Alpinia zerumbet in mice.Microinterventions targeting regulatory focus and regulatory fit selectively reduce dysphoric and anxious mood The National Institute of Mental Health Research Domain Criteria and Clinical Research in Child and Adolescent Psychiatry Subgenual cingulate cortical activity predicts the efficacy of electroconvulsive therapy Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference.Translational Assessment of Reward and Motivational Deficits in Psychiatric Disorders.Cognitive Flexibility: A Default Network and Basal Ganglia Connectivity Perspective.Elevated morning cortisol is a stratified population-level biomarker for major depression in boys only with high depressive symptoms The innovative medicines initiative: a public private partnership model to foster drug discovery.Value added medicines: what value repurposed medicines might bring to society?Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases?Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders.The role of habit in compulsivity.Studying human disease using human neurons.Translational Neuroscience as a Tool for Intervention Development in the Context of High-Adversity Families.Cognitive Translation Using the Rodent Touchscreen Testing Approach.Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.Zebrafish models in neuropsychopharmacology and CNS drug discovery.Pharmacotherapy in Generalized Anxiety Disorder: Novel Experimental Medicine Models and Emerging Drug Targets.The role of 5-HT2C receptors in touchscreen visual reversal learning in the rat: a cross-site study.Development of a translational model to screen medications for cocaine use disorder I: Choice between cocaine and food in rhesus monkeys.Treatment of eating disorders can not remain 'brainless': the case for brain-directed treatments.Cognitive Training Using a Novel Memory Game on an iPad in Patients with Amnestic Mild Cognitive Impairment (aMCI).Rigor and Reproducibility in Rodent Behavioral Research.Cognitive Training Using a Novel Memory Game on an iPad in Patients with Amnestic Mild Cognitive Impairment (aMCI).

P2860

Q26744718-73906E70-A722-43B3-8E01-0FC5DECF21B7 Q26776476-6BF4F3B1-DBB0-4EFF-AF56-276B43D29455 Q26783012-216F4864-3521-4B55-B4A5-9710C3CA26C3 Q26799352-C3735E35-3210-48B0-8951-C1017C76283D Q27008349-9076E191-CC71-463C-A35D-6175327D6CBD Q30366697-A497ED46-495D-4D27-9804-2CCE772CC2ED Q30976676-86106BBD-0884-4ABA-82E1-71B313E7DD50 Q34071914-D6BCC197-4C0C-4F1D-8CFC-4AE81CDCBC08 Q34109804-3A7C74E5-DCDB-4955-9D63-5660B203FC85 Q34207159-BA8871F0-79C9-4475-87EC-1174FA61C411 Q34405264-5E8B9202-AF7E-4359-9863-7403BF74546B Q35224273-766FE4FF-2696-493A-A05F-A0D9DA7D6D62 Q35369988-839FACCF-FC85-498E-AACE-24C982244FF1 Q35557270-89C31C40-E618-4510-B5F5-B784C00216EB Q35606297-2F1E4B49-AFDC-4F49-9465-FF5568E5B196 Q35930419-ACA9C814-66E1-4584-B8CD-CBA139732276 Q36494454-CFDB3293-8ED2-4B24-9F01-89E1EDE84C62 Q36915400-E3024AF9-5C58-4B8E-A084-D90A557DC896 Q37038637-0D2D37C2-C182-47CA-A474-973E2A893966 Q37171853-AE72938A-67FC-4C2E-A1C7-249F7516AC44 Q37428544-D46EC229-631E-4C9A-9B6E-53110CCFE901 Q37627952-295FC7BF-5861-4A8F-882B-435F32E5BA59 Q37655104-71C5E63D-35FF-4237-AAF1-FE1B91682D57 Q37669600-404D06DF-EC6C-4546-AD3A-595205D08AE2 Q37670707-42E97E1E-3FF4-4C92-BC20-44F4BE2F3632 Q38592069-14F92403-652E-40B3-A054-3F071FF88B41 Q38629117-9D737A25-436C-42C5-97EE-35408D3912C3 Q38698930-4BBDF456-5D11-416E-A5A5-A6CA158FED34 Q38802823-8A75BC3A-F6AA-4DD9-8782-30678ECC372D Q38824927-592F537B-E71C-4D2E-9DF7-4297E2A1507D Q38865916-42CB3B82-53F2-442B-B7AB-8B0A439EDDDD Q38969500-E1BFEC01-0C6E-4CAC-A6AD-180DDD7964ED Q39144048-A9D6FF57-124A-4906-9010-E7E094A03519 Q39183229-4C4AE4B2-C42A-4A5B-9BF0-5615F84467E7 Q42254092-5BA4737D-C9CD-405B-98BA-D278C287F60C Q42426966-D14A1424-FEF4-46B9-A66E-26C3252063C4 Q44888143-46A4D4F3-6201-411C-9077-F1EC7777403F Q47157811-520B0186-D614-4B6A-8F0B-DB083298CA66 Q47200848-FEAF679D-892A-4236-9EDD-F224242EC6C3 Q47321397-1A1ED15A-6866-405B-AAD8-BF38ACB9711A

P2860

Innovative solutions to novel drug development in mental health

http://www.wikidata.org/entity/Q28677399

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Innovative solutions to novel drug development in mental health

@ast

Innovative solutions to novel drug development in mental health

@en

Innovative solutions to novel drug development in mental health

@nl

type

label

Innovative solutions to novel drug development in mental health

@ast

Innovative solutions to novel drug development in mental health

@en

Innovative solutions to novel drug development in mental health

@nl

prefLabel

Innovative solutions to novel drug development in mental health

@ast

Innovative solutions to novel drug development in mental health

@en

Innovative solutions to novel drug development in mental health

@nl

P1433

Q28677399-4A6AA028-13AF-4561-BAF5-90F086179355

P1476

Q28677399-4E97F527-2922-48EC-9DB3-C98CE4DF7A37

P2093

Q28677399-00BFA57E-B3EE-4409-974F-B3E412D55056

Q28677399-02322B39-2E19-4A6B-A806-04D327D666FA

Q28677399-0912ED0A-3396-41BA-89CA-AB9C9A68AB9B

Q28677399-25D0A466-8E9A-45A0-9797-434A7F8D21A7

Q28677399-292FA0E3-7418-49E9-A3BA-055A9F43D6AE

Q28677399-297E1355-965B-414F-9336-0F875F7D88F3

Q28677399-439CDBA2-C041-4A0C-9520-761A6BCCEEB3

Q28677399-453C4886-8A1F-4264-8340-8B803A8278C7

Q28677399-5DBB915C-DD91-4A12-9D9B-7DECDEDD029C

Q28677399-60E27AB7-B929-4FFC-825A-CFD0CD892AA5

P275

Q28677399-A711A194-2471-42BF-8707-1A347FDF5CCE

P2860

Q28677399-021322D2-2676-4845-AA01-329F40732F79

Q28677399-0332296A-79F6-4F11-9964-521D5CCB043F

Q28677399-086A1F84-6AA3-4289-AEAE-55BB25702CF8

Q28677399-1E56EBE4-310A-4B3D-A424-A6526C0E3791

Q28677399-20615D43-9460-46ED-A064-24880E69DA6E

Q28677399-2EC27304-8B66-450F-B918-F0F866B3F6F0

Q28677399-2F9D1E34-542D-4370-95B2-D8DB3247182D

Q28677399-33EE6408-09CC-4D38-96A1-40C10C836FF1

Q28677399-37F3CE5E-E088-40BF-B1C2-7B71CB90DC31

Q28677399-3BFCF4D5-B4EB-404C-8A10-C48EA2C02298

P304

Q28677399-90658606-F353-46C2-B572-D3CDF51EA200

P31

Q28677399-1FA1ED41-F67B-4BD6-BB5F-982603D57F96

Q28677399-5187A5F4-857C-481B-B7AE-81DBF6F497CB

P3181

Q28677399-F2A87B23-58D7-4968-8802-DF67A2D029C8

P356

Q28677399-06E8FF44-E862-4C82-9D5F-7EE4CF552EEF

P407

Q28677399-9641D62C-264C-4F2B-A88F-5717CB3801EA

P433

Q28677399-29A64E0C-B3DF-4EE2-8669-84CF07F6C320

P478

Q28677399-35AB5706-6EAE-4F1C-BE10-B67B6C1517F2

P50

Q28677399-8500AC24-A25A-42E9-BC5B-BF14FAEBF801

P5008

Q28677399-A3C3190D-583A-43E1-AFE7-DDC6D09BAAEF

P577

Q28677399-9107A73B-BBDB-483B-8D5C-08910B3542AB

Q28677399-D5558A09-6A17-4614-BC8E-11A4BC2F8323

P5875

Q28677399-5C2BBC83-C0E3-4744-B66F-ADF110EA2C91

P698

Q28677399-6C06670A-DF7F-454F-B0EF-37F628F44576

P921

Q28677399-44D6BF92-1A75-47AE-BA2B-789DE6AB6096

Q28677399-4B8FC16A-40DA-44C0-90D5-8FD36A3E4EC4

Q28677399-EF9BA20F-AA38-4FE0-BD06-11BB56B0FC9C

P932

Q28677399-F5833353-1B7F-47AE-A122-B5E0A984C02E

P3181

P356

J.NEUBIOREV.2013.03.022

P1433

Neuroscience & Biobehavioral Reviews

P1476

Innovative solutions to novel drug development in mental health

@en

P2093

B J Sahakian

http://www.w3.org/2001/XMLSchema#string

B M Altevogt

http://www.w3.org/2001/XMLSchema#string

D J Kupfer

http://www.w3.org/2001/XMLSchema#string

D J Nutt

http://www.w3.org/2001/XMLSchema#string

E T Bullmore

http://www.w3.org/2001/XMLSchema#string

G M Goodwin

http://www.w3.org/2001/XMLSchema#string

G Malloch

http://www.w3.org/2001/XMLSchema#string

H M Marston

http://www.w3.org/2001/XMLSchema#string

J H Williams

http://www.w3.org/2001/XMLSchema#string

J S Nye

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

Initial impact of the sequencing of the human genome

Grand challenges in global mental health

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

Modelling schizophrenia using human induced pluripotent stem cells.

Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial

Genome-wide association study identifies five new schizophrenia loci

Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4

P304

2438-44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1542282

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.NEUBIOREV.2013.03.022

http://www.w3.org/2001/XMLSchema#string

P407

P433

10 Pt 1

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236127793

http://www.w3.org/2001/XMLSchema#string

P698

23563062

http://www.w3.org/2001/XMLSchema#string

P921

mental disorder

biomedical investigative technique

P932

3788850

http://www.w3.org/2001/XMLSchema#string